DC Chemicals

DC67567 · Updated 28 October 2026

ARV-T1

Literature evidence · DC67567

Formulation & Performance

Reporter kinetics, vaccine antibody responses, storage stability and tolerability are separate evidence endpoints.

Reported performance refers to the complete research formulation and the stated experimental model.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
ARV-T1DC67567910.51500.455255
DSPCDC57005790.15100.079015
CholesterolDCD-041386.6538.50.148860
DMG-PEG2000DC4016925071.50.037605

ARV-T1/DSPC/cholesterol/DMG-PEG2000 = 50:10:38.5:1.5 mol%; reported N/P = 4. Source: Methods, LNP formulation. DMG-PEG2000 uses 2507 for calculated component masses. A lipid:RNA mass ratio is not inferred from N/P.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
ARV-T1——
DSPC——
Cholesterol——
DMG-PEG2000——

Particle properties

Experiment / parameterStudy conditionsResult / interpretation
Apparent pKaTNS assay on LNPs without encapsulated mRNA; Fig. 2F6.73; this is a formulation-dependent measurement, not an isolated-molecule pKa.
Hydrodynamic sizeFig. 2 and DiscussionApproximately 80 nm for ARV-T1 versus 90 nm for the SM-102 comparator.
EncapsulationFig. 2Both formulations exceeded 90% RNA encapsulation.
Dispersity and surface potentialFig. 2ARV-T1 showed lower PDI and greater absolute zeta potential than the comparator; the text describes magnitudes of approximately 10 versus 5 mV.

Cellular expression and viability

Experiment / parameterStudy conditionsResult / interpretation
Protein expressionHEK293T cell experiments; Fig. 3ARV-T1 LNPs produced higher antigen expression than the matched SM-102 formulation. No fold change is inferred from chart heights.
Cell viabilityHEK293T and Huh7; 48 h; Fig. 7ANo significant reduction was reported across most tested concentrations; a high-concentration effect was observed in Huh7 at 125 µM.

Intramuscular reporter kinetics

Experiment / parameterStudy conditionsResult / interpretation
Study conditionsBALB/c mice, n = 6; 1 µg luciferase mRNA IMLuminescence assessed at 6, 24, 48 and 72 h (Fig. 5).
ARV-T1 expressionPeak at 24 hApproximately 50% of peak signal remained at 72 h.
SM-102 comparatorPeak at 6 hSignal declined rapidly and was barely detectable at 72 h in this experiment.

Antibody responses

Experiment / parameterStudy conditionsResult / interpretation
Prime/boost studyMouse immunization on days 1 and 21; readouts days 14 and 35; Fig. 6The authors report >10-fold higher potency for antigen-binding and neutralizing-antibody responses compared with the study SM-102 formulation.
Dose-response interpretationLow-dose vaccine comparisonsAntibody potency is not a measure of tenfold higher transfection in every tissue, and is not a human vaccine efficacy estimate.

Storage and in vivo tolerability

Experiment / parameterStudy conditionsResult / interpretation
Frozen storage12 weeks at −20°C versus −80°C; Fig. 4CCellular protein expression was similar, although PDI increased at −20°C.
Refrigerated storage12 weeks at 4°C; Fig. 4CApproximately 50% fewer antigen-positive cells and 66% lower median fluorescence than the frozen groups.
Repeated IM administrationTwo doses separated by three weeks; Fig. 7Blood chemistry one day after the last dose and tissue histology two weeks later showed no reported abnormal changes; body weight was not significantly altered.
ScopeStudy formulation and observation windowsThe study does not establish human, chronic or unrestricted-dose safety. Storage findings do not define the isolated reagent shelf life.

Original study figures

Cell expression, storage, mouse expression and tolerability: Figures 3–7 — Original source figures.

References and source locations

  1. Jeon JH, et al. Lipid Nanoparticles Formulated with a Novel Cholesterol-Tailed Ionizable Lipid Markedly Increase mRNA Delivery Both in vitro and in vivo. International Journal of Nanomedicine 20, 9389–9405 (2025). DOI: 10.2147/IJN.S527822.
  2. Full text: formulation Methods and Figures 2–7.